Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody

Navigator Medicines has launched with a $100 million Series A funding round co-led by RA Capital Management and Forbion.
The company aims to advance a bispecific antibody drug targeting OX40L and TNFα for the treatment of autoimmune diseases.
The bispecific antibody was licensed from South Korea-based IMBiologics.
Dana McClintock has been appointed as the chief medical officer of Navigator Medicines.